View On Demand

Upstream AAV Production: A Targeted Approach to Optimization

This webinar will discuss some of the key upstream process parameters to consider for efficient and scalable AAV production with a focus on the transfection step.

Click here to view on demand.

Key messages:

  • What are the critical upstream parameters for AAV production?​
  • What early process considerations are required to ensure success at large scale?​
  • What high-throughput technologies can accelerate development timelines and deliver a robust platform?​
  • How can innovation drive a fast-changing landscape?

Agenda:

  1. What AAV attributes are important to ensure high-yield and high-quality AAV production?  
    • Performance and quality attributes: titre, infectivity, E:F, impurities​
    • Cell line/Media importance​
    • Transfection as a critical step: show different approaches are possible and why chemical based is the method of choice​
    • Improvement of AAV production phase: mechanisms to improve titres, lysis vs non lysis and serotype impact. 
  2. ​What is Pharmaron's current approach?
    • Platform process and feasibility studies to assess fit (including impact to DSP)​
    • Use of high-throughput technology in combination with DoE to optimise key parameters​
    • Importance of scale-up with a focus on transfection​
    • Pharmaron’s AAV USP platform performance (yield, impurities, infectivity data)​
    • Introduce Polyplus and importance of collaboration​
  3. Collaboration and trial of transfection reagent​
    • Introduction to Polyplus and their products​
    • Presentation of Pharmaron Beta testing data​
    •  Presentation of internal Pharmaron data using Polyplus product

Click here to view on demand. 

Moderated by: Derek Ellison, Ph.D. - Vice President, Biologics Services Europe at Pharmaron Gene Therapy

Key Opinion Leader: Professor Alan Dickson - Professor of Biotechnology at Centre of Excellence in Biopharmaceuticals, University of Manchester 

Alan is a Professor of Biotechnology at the University of Manchester and has primary research interests in the industrial applications of mammalian cells as factories for the production of therapeutic recombinant proteins and viral vectors.  Alan directs at the Manchester Centre of Excellence in Biopharmaceuticals and is part of the organizational group for BioProNET2, both of which promote collaborations at the industrial/academic interface.

Speakers: 

Hélène Trottin - Senior Technical Specialist, Process Sciences at Pharmaron Gene Therapy

Following her Biochemical Engineering studies in France, Hélène Trottin started her career in the UK by developing processes for the production of recombinant proteins. She has 9-years of experience in the pharmaceutical industry, leading both early and late stage projects for a range of biologics products. Currently based in Liverpool (UK), she works for Pharmaron as a Senior Technical Specialist, providing expertise and leadership in upstream process development and tech transfer of gene therapy products. In parallel to her work, she is also studying for an MBA, through the Senior Leader Master’s Degree Apprenticeship (SLMDA) program.

Cassie-Marie Peigné, Ph.D. - Scientific Support Specialist at Polyplus

Cassie-Marie Peigné, PhD. is a Support Specialist at Polyplus-transfection® SA, the leading biotechnology company that supports Gene and Cell therapy, biologics manufacturing and life science research with innovative nucleic acid transfection solutions.  Before joining Polyplus, Cassie completed her PhD in Immunology at the University of Nantes, followed by a postdoctoral position in Infectious Diseases at the Okinawa Institute of Science and Technology.

More Information

CGT Webinar Series Home

Learn About Our Services